Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
PRIMARY OBJECTIVES:
I. Assess the MTD of cediranib in combination with olaparib in the treatment of recurrent
ovarian, fallopian tube, or peritoneal cancer or metastatic triple-negative breast cancer.
(Phase I) II. Assess the efficacy (as measured by progression-free survival (PFS) ) of the
combination of cediranib and olaparib compared to olaparib alone in recurrent grade 2 or 3
platinum-sensitive papillary-serous or endometrioid ovarian, fallopian tube, or peritoneal
cancer. (Phase II)
SECONDARY OBJECTIVES:
I. Assess the toxicities of the combination of cediranib and olaparib in the treatment of
recurrent ovarian, fallopian tube, or peritoneal cancer or metastatic triple-negative breast
cancer. Assess clinical benefit, progression-free survival, and overall survival for
patients treated with cediranib and olaparib. (Phase I) II. Assess tumor response, clinical
response benefit (response or stable disease as defined by RECIST response criteria x 16
weeks), and overall survival (OS) for patients treated with cediranib and olaparib at the
RP2D as compared with patients receiving olaparib alone. (Phase II)
TERTIARY OBJECTIVES:
I. To evaluate the prognostic and predictive role of measured changes in functional vascular
imaging using DCE-MRI between pre-study and day 3. (Phase II) II. To evaluate in an
exploratory fashion the predictive or prognostic value of SNPs in key genes involved in
angiogenesis and DNA repair. (Phase II) III. To evaluate the predictive value of baseline
PBMC PAR incorporation on response to therapy. (Phase II) IV. To measure early changes in
vascular cytokine production and evaluate in an exploratory fashion that these changes may
be predictive or prognostic, or differentially affected by the combination of agents. (Phase
II) V. To evaluate early changes to circulating endothelial cells and if these changes are
predictive or prognostic. (Phase II) VI. To assess changes in measures of DNA damage and
repair and angiogenesis in tumor cells (tissue and/or malignant effusions) and correlate to
drug/drug/combination. (Phase II)
OUTLINE:
In the first part of the study, since we were looking for the highest dose of the study drug
that can be administered safely without severe or unmanageable side effects, not everyone
who participated in this part of the research study received the same dose of the study
drug. This portion of the study has now completed.
In the second portion of the study, participants will be randomized to receive either the
combination of cediranib and olaparib or to receive olaparib alone. Participants will know
which arm they have been randomized to, but do not have any control over which arm it will
be.
Each cycle lasts four weeks (28 days), and participants will be taking the study drugs for
the entire four weeks. Participants will take drugs orally as specified in the given
treatment arm. Cediranib tablets will be taken once in the morning and olaparib capsules
will be taken twice a day.
Participants will be asked to monitor their blood pressure on a twice daily basis at home
and keep a blood pressure diary. The following tests and procedures will be performed at
specific time intervals while the participant is on the study: physical exam, vital signs,
blood tests, CT scan/MRI, urine test and ECG.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of cediranib in combination with olaparib (Phase I)
28 days
Yes
Joyce Liu
Principal Investigator
Dana-Farber Cancer Institute
United States: Food and Drug Administration
NCI-2012-02938
NCT01116648
March 2010
Name | Location |
---|---|
Johns Hopkins University | Baltimore, Maryland 21205 |
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Beth Israel Deaconess Medical Center | Boston, Massachusetts 02215 |
Loyola University Medical Center | Maywood, Illinois 60153 |
Massachusetts General Hospital Cancer Center | Boston, Massachusetts 02114 |
Ingalls Memorial Hospital | Harvey, Illinois 60426 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Cedars-Sinai Medical Center | Los Angeles, California 90048 |
Central Illinois Hematology Oncology Center | Springfield, Illinois 62701 |
Newton-Wellesley Hospital | Newton, Massachusetts 02462 |
Decatur Memorial Hospital | Decatur, Illinois 62526 |
University of Chicago Comprehensive Cancer Center | Chicago, Illinois 60637-1470 |
Froedtert and the Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |
Evanston CCOP-NorthShore University HealthSystem | Evanston, Illinois 60201 |
Illinois CancerCare-Peoria | Peoria, Illinois 61615 |
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard | Fort Wayne, Indiana 46845 |
Saint John's Mercy Medical Center | Saint Louis, Missouri 63141 |
University of Maryland Greenebaum Cancer Center | Baltimore, Maryland 21201 |
University of Michigan University Hospital | Ann Arbor, Michigan 48109 |
Southern Illinois University | Springfield, Illinois 62702 |